Phase III study of MLN0002 (300 mg) in treatment of Crohn's disease
Phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and pharmacokinetics of intravenous MLN0002 (300 mg) infusion in induction and maintenance therapy in Japanese subjects with moderate or severe Crohn's disease Phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to eval ...
Crohn's disease
Intervention name : MLN0002 (Vedolizumab) INN of the intervention : Vedolizumab Dosage And administration of the intervention : Vedolizumab (300 mg) administered by intravenous infusion at Weeks 0, 2, and 6 and every 8 weeks thereafter. Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : VedolizumabPlacebo administered by intravenous infusion at Weeks 0, 2, and 6 and every 8 weeks thereafter. Intervention name : MLN0002 (Vedolizumab) INN of the intervention : Vedolizumab Dosage And administrat ...